Cas no 118072-93-8 (Zoledronic acid)
Zoledronic acid Chemical and Physical Properties
Names and Identifiers
-
- (1-Hydroxy-2-(1H-imidazol-1-yl)ethane-1,1-diyl)diphosphonic acid
- Zoledronic acid hydrate
- ZOLEDRONATE
- [1-hydroxy-2-(1h-imidazol-1-yl)-ethylidene]bisphosphonic acid
- 2-(Imidazol-1-yl)-1-hydroxyethane-1,1-diphosphonic Acid
- CGP-4244
- Zoledronic acid
- [1-hydroxy-2-(1H-imidazol-1-yl)ethane-1,1-diyl]bis(phosphonic acid) monohydrate
- CGP 42446
- CGP42446A
- P,P′-[1-Hydroxy-2-(1H-imidazol-1-yl)ethylidene]bisphosphonic acid monohydrate
- ZOL 446
- Zoledronic acid monohydrate
- Zometa,Zomera,Aclasta and Reclast
- Orazol
- BPH 91
- ZoMeta
- Aclasta
- Reclast
- CGP-42446
- Zoledronic
- (1-Hydroxy-2-imidazol-1-ylethylidene)diphosphonic acid
- Zomera
- ZOL
- Aclasta and Reclast
- [1-hydroxy-2-(1H-imidazol-1-yl)ethane-1,1-diyl]bis(phosphonic acid)
- Zometa (TN)
- Phosphonic acid, [1-hydroxy-2-(1H-imidazol-1-yl)ethylidene]bis-
- 70HZ18PH24
- [1-hydroxy-2-(1H-imidazol-1-yl)-1-phosphonoethyl]phosphonic acid
- EN300-117269
- AB01273947-01
- NCGC00159521-04
- NCGC00159521-05
- CHEBI:46557
- ZOLEDRONIC ACID [INN]
- HS-0091
- Zoledronic acid (INN)
- C5H10N2O7P2
- Zometa (Novartis)
- STL452893
- NCGC00159521-02
- DTXCID8022668
- (1-hydroxy-2-imidazol-1-yl-1-phosphonoethyl)phosphonic acid
- Z1501485360
- Phosphonic acid, (1-hydroxy-2-(1H-imidazol-1-yl)ethylidene)bis-
- AB01273947-02
- CS-1829
- DB00399
- DTXSID0042668
- AB07564
- D08689
- JMC515594 Compound 55
- CAS-118072-93-8
- S00092
- SR-05000001436-1
- 1-Hydroxy-2-(1-imidazolyl)ethane-1,1-diphosphonic Acid
- zoledronic-acid
- AKOS005145739
- 118072-93-8
- Bisphosphonate 3
- HB0674
- (1-Hydroxy-2-(1H-imidazol-1-yl)ethane-1,1-diyl)diphosphonicacid
- AC-1092
- ZOLEDRONIC ACID [WHO-DD]
- Zoledronic Acid?
- H11422
- (1-hydroxy-2-(1H-imidazol-1-yl)ethylidene)bisphosphonic acid
- NSC 721517
- BIDD:GT0292
- NCGC00159521-09
- 1-hydroxy-2-(1H-imidazol-1-yl)ethane-1,1-diyldiphosphonic acid
- Zoledronic Acid (Zoledronate)
- BRD-K84253429-001-04-4
- SCHEMBL19054
- Anhydrous Zoledronic Acid
- s1314
- Q218507
- Reclast (TN)
- BCP22750
- NS00006387
- Tox21_111739
- 1-Hydroxy-2-(1H-imidazol-1-yl)ethylidene]-bisphosphonic Acid Hydrate; 2-(Imidazol-1-yl)-1-hydroxyethane-1,1-diphosphonic Acid Hydrate;
- GTPL3177
- Zoledronic acid [USAN:INN:BAN]
- NCGC00159521-03
- Q-201946
- SR-05000001436
- MFCD00867791
- ZOLEDRONIC ACID [MI]
- BIDD:PXR0134
- BDBM12578
- NSC721517
- AB01273947_04
- UNII-70HZ18PH24
- HY-13777
- AB01273947-03
- NSC-721517
- HMS2089O09
- NCGC00159521-18
- BRD-K84253429-001-03-6
- CHEMBL924
- Zoledronic acid, Zoledronate
- Z0031
- Zoledronic Acid, Anhydrous
- Zoledronic Acid Anhydrous
-
- MDL： MFCD00867791
- Inchi： 1S/C5H10N2O7P2/c8-5(15(9,10)11,16(12,13)14)3-7-2-1-6-4-7/h1-2,4,8H,3H2,(H2,9,10,11)(H2,12,13,14)
- InChI Key： XRASPMIURGNCCH-UHFFFAOYSA-N
- SMILES： C(O)(CN1C=CN=C1)(P(=O)(O)O)P(=O)(O)O
Computed Properties
- Exact Mass: 271.99600
- Monoisotopic Mass: 271.996
- Isotope Atom Count: 0
- Hydrogen Bond Donor Count: 5
- Hydrogen Bond Acceptor Count: 8
- Heavy Atom Count: 16
- Rotatable Bond Count: 4
- Complexity: 327
- Covalently-Bonded Unit Count: 1
- Defined Atom Stereocenter Count: 0
- Undefined Atom Stereocenter Count : 0
- Defined Bond Stereocenter Count: 0
- Undefined Bond Stereocenter Count: 0
- Surface Charge: 0
- Tautomer Count: nothing
- XLogP3: -4.3
- Topological Polar Surface Area: 153
Experimental Properties
- Color/Form: White crystalline powder
- Density: 2.13
- Melting Point: 193-2040C (dec)
- Boiling Point: 764°C at 760 mmHg
- Flash Point: 415.8°C
- Refractive Index: 1.718
- PSA: 172.73000
- LogP: -1.11540
- Vapor Pressure: 1.53E-24mmHg at 25°C
Zoledronic acid Security Information
- Signal Word：Warning
- Hazard Statement： H315-H319-H335
- Warning Statement： P261-P305+P351+P338
- Hazard Category Code： R21/22: harmful by skin contact and careless swallowing. R36/37/38: irritating to eyes, respiratory tract and skin.
- Safety Instruction： S24/25; S36/37/39
-
Hazardous Material Identification：
- Storage Condition：Please store the product under the recommended conditions in the Certificate of Analysis.
- Risk Phrases：R21/22
Zoledronic acid Customs Data
- Customs Data：
China Customs Code:
2933290090Overview:
2933290090. Other compounds with non fused imidazole ring in structure. VAT:17.0%. Tax refund rate:13.0%. Regulatory conditions:nothing. MFN tariff:6.5%. general tariff:20.0%
Declaration elements:
Product Name, component content, use to, Please indicate the appearance of Urotropine, 6- caprolactam please indicate the appearance, Signing date
Summary:
2933290090. other compounds containing an unfused imidazole ring (whether or not hydrogenated) in the structure. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0%
Zoledronic acid Pricemore >>
| Related Categories | No. | Product Name | Cas No. | Purity | Specification | Price | update time | Inquiry |
|---|---|---|---|---|---|---|---|---|
| SHANG HAI A LA DING SHENG HUA KE JI GU FEN Co., Ltd. | Z129382-1g |
Zoledronic acid |
118072-93-8 | ≥99% | 1g |
￥358.90 | 2023-08-31 | |
| SHANG HAI A LA DING SHENG HUA KE JI GU FEN Co., Ltd. | Z129382-100mg |
Zoledronic acid |
118072-93-8 | ≥99% | 100mg |
￥133.90 | 2023-08-31 | |
| SHANG HAI A LA DING SHENG HUA KE JI GU FEN Co., Ltd. | Z129382-25g |
Zoledronic acid |
118072-93-8 | ≥99% | 25g |
￥2374.90 | 2023-08-31 | |
| SHANG HAI A LA DING SHENG HUA KE JI GU FEN Co., Ltd. | Z129382-25mg |
Zoledronic acid |
118072-93-8 | ≥99% | 25mg |
￥61.90 | 2023-08-31 | |
| SHANG HAI A LA DING SHENG HUA KE JI GU FEN Co., Ltd. | Z129382-5g |
Zoledronic acid |
118072-93-8 | ≥99% | 5g |
￥1173.90 | 2023-08-31 | |
| S e l l e c k ZHONG GUO | S1314-25mg |
Zoledronic acid (ZOL 446) |
118072-93-8 | 99.80% | 25mg |
￥564.29 | 2023-09-15 | |
| S e l l e c k ZHONG GUO | S1314-100mg |
Zoledronic acid (ZOL 446) |
118072-93-8 | 99.80% | 100mg |
￥1711.23 | 2023-09-15 | |
| SHANG HAI YI EN HUA XUE JI SHU Co., Ltd. | R002865-1g |
Zoledronic acid |
118072-93-8 | 98% | 1g |
￥180 | 2023-09-10 | |
| SHANG HAI YI EN HUA XUE JI SHU Co., Ltd. | R002865-25g |
Zoledronic acid |
118072-93-8 | 98% | 25g |
￥3274 | 2023-09-10 | |
| SHANG HAI YI EN HUA XUE JI SHU Co., Ltd. | R002865-5g |
Zoledronic acid |
118072-93-8 | 98% | 5g |
￥668 | 2023-09-10 |
Zoledronic acid Suppliers
Audited Supplier
Zoledronic acid Related Literature
-
Tomasz Rojek,Waldemar Goldeman,Katarzyna ?lepokura,Marek Duczmal,Agnieszka Wojciechowska,Ewa Matczak-Jon Dalton Trans. 2017 46 6900
-
Alessandra Barbanente,Nicoletta Ditaranto,Antonio Laghezza,Paolo Tortorella,Francesco P. Intini,Concetta Pacifico,Giovanni Natile,Nicola Margiotta Dalton Trans. 2023 52 6117
-
Tomasz Rojek,Waldemar Goldeman,Katarzyna ?lepokura,Marek Duczmal,Agnieszka Wojciechowska,Ewa Matczak-Jon New J. Chem. 2018 42 7830
-
Demin Liu,Chunbai He,Christopher Poon,Wenbin Lin J. Mater. Chem. B 2014 2 8249
-
Hélène Roussière,Gilles Montavon,Samia La?b,Pascal Janvier,Bruno Alonso,Franck Fayon,Marc Petit,Dominique Massiot,Jean-Michel Bouler,Bruno Bujoli J. Mater. Chem. 2005 15 3869
Additional information on Zoledronic acid
Introduction to Zoledronic Acid (CAS No: 118072-93-8) and Its Latest Research Applications
Zoledronic acid, chemically known by its CAS number 118072-93-8, is a potent bisphosphonate compound that has garnered significant attention in the field of pharmaceutical chemistry and medicine. This compound belongs to the class of nitrogen-containing bisphosphonates, which are synthetic analogs of pyrophosphate ions. Zoledronic acid is widely recognized for its ability to inhibit osteoclast-mediated bone resorption, making it a cornerstone in the treatment of various bone-related disorders. Its molecular structure, characterized by a pyridine ring and multiple phosphonate groups, contributes to its high affinity for hydroxyapatite, the primary mineral component of bone tissue.
The pharmacological significance of Zoledronic acid (CAS No: 118072-93-8) lies in its mechanism of action, which involves the binding to hydroxyapatite crystals in bone matrices. This binding prevents the enzyme tartrate-resistant acid phosphatase (TRAP) from functioning, thereby inhibiting osteoclast activity. As a result, bone resorption is significantly reduced, leading to increased bone density and reduced fracture risk. This mechanism has made Zoledronic acid a first-line therapeutic agent in conditions such as osteoporosis, Paget's disease of bone, and hypercalcemia of malignancy.
Recent advancements in the study of Zoledronic acid (CAS No: 118072-93-8) have expanded its therapeutic applications beyond traditional indications. For instance, research has highlighted its potential role in the treatment of certain types of cancer. Studies have demonstrated that Zoledronic acid can induce apoptosis in cancer cells by modulating various signaling pathways, including the nuclear factor kappa B (NF-κB) pathway. Additionally, its ability to inhibit angiogenesis has been explored as a strategy to impede tumor growth and metastasis.
In clinical trials, Zoledronic acid has been administered via intravenous routes due to its poor oral bioavailability. The drug's rapid clearance from the bloodstream necessitates repeated dosing for long-term therapeutic effects. However, recent research has focused on optimizing delivery systems to enhance efficacy while minimizing side effects. Nanoparticle-based delivery systems and sustained-release formulations are among the emerging strategies that aim to improve the pharmacokinetics of Zoledronic acid (CAS No: 118072-93-8).
The safety profile of Zoledronic acid is well-documented, with common side effects including osteonecrosis of the jaw (ONJ) and atypical femoral fractures (AFF). These adverse effects are primarily attributed to prolonged suppression of osteoclast activity. To mitigate these risks, guidelines recommend periodic monitoring and adherence to appropriate dosing regimens. Despite these concerns, Zoledronic acid remains a highly effective treatment option for patients with severe bone disorders.
Emerging research also suggests that Zoledronic acid (CAS No: 118072-93-8) may have applications in neurodegenerative diseases. Preliminary studies have indicated that it can modulate inflammatory responses and protect against neuronal damage in models of Alzheimer's disease and Parkinson's disease. While further investigation is needed to validate these findings, they open up new avenues for exploring the therapeutic potential of this compound.
The synthesis and structural modifications of Zoledronic acid continue to be areas of active research. Chemists are exploring novel analogs with improved pharmacological properties, such as enhanced selectivity and reduced toxicity. These efforts aim to develop next-generation bisphosphonates that can address unmet medical needs more effectively.
In conclusion, Zoledronic acid (CAS No: 118072-93-8) is a multifaceted compound with broad therapeutic implications in medicine. Its ability to inhibit bone resorption makes it indispensable in treating bone-related disorders, while its potential applications in cancer therapy and neurodegenerative diseases highlight its versatility. Ongoing research continues to uncover new insights into its mechanisms of action and expand its clinical utility.
118072-93-8 (Zoledronic acid) Related Products
- 165800-07-7(Zoledronic Acid Disodium Salt Tetrahydrate)
- 904894-54-8(Zoledronic Acid Trihydrate)
- 1134798-26-7(Zoledronic-d3 Acid)
- 118054-40-3(2-(1H-Imidazol-1-yl)ethylidenediphosphonic acid)
- 131654-46-1(Phosphonic acid, P,P'-[1-hydroxy-2-(1H-imidazol-1-yl)ethylidene]bis-, sodium salt (1:2))
- 165800-06-6(Zoledronic acid monohydrate)
- 827573-11-5(Zoledronate trisodium anhydrous)
- 849813-90-7(Phosphonic acid, [2-(1H-benzimidazol-1-yl)-1-hydroxyethylidene]bis-)
- 183447-56-5(Phosphonic acid, [1-hydroxy-4-(1H-imidazol-1-yl)butylidene]bis-)
- 165800-08-8(Phosphonic acid,[1-hydroxy-2-(1H-imidazol-1-yl)ethylidene]bis-, trisodium salt, hydrate (5:2)(9CI))
